The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase III trial of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting, was successful in achieving statistical significance for its primary and all secondary endpoints.
In a phase I study, tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Merck announced new biomarker findings from a retrospective analysis of the completed phase III study that compared Erbitux (cetuximab) plus FOLFIRI with FOLFIRI alone.
A study found that it may be safe to postpone androgen deprivation therapy in men with a PSA-only based relapse after prostate surgery or radiation therapy.
The American Society of Clinical Oncology published two clinical practice guidelines on treating women with advanced, HER2-positive breast cancer.
A model projecting outcomes for nationwide low-dose CT screening for lung cancer estimated that gradual implementation of the program would detect roughly 54,900 more cases over five years in a high-risk Medicare population. The large majority of new cases would be early-stage disease.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
The American Society of Clinical Oncology published three clinical practice guidelines for the prevention and management of neuropathy, fatigue, depression, and anxiety.
A phase I single-arm study of LDK378 (ceritinib) demonstrated an overall response rate of 58 percent in patients with ALK-positive non-small cell lung cancer. Patients who received 400 mg or higher of LDK378 per day had a median progression-free survival of seven months.
